Primary evaluation and management of statin therapy complications

Southern Medical Journal

Volumn 99, Issue 3, 2006, Pages 250-256

  Seehusen, Dean A ^a   Asplund, Chad A ^a   Johnson, Dawn R ^a   Horde, Kevin A ^a  

^a EISENHOWER ARMY MEDICAL CENTER   (United States)

Author keywords

Adverse effects; Cholesterol; Hydroxymethylglutaryl CoA reductase inhibitors; Liver function tests; Myopathy

Indexed keywords

AMIODARONE; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CYCLOSPORIN DERIVATIVE; DILTIAZEM; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; NICOTINIC ACID; PRAVASTATIN; PYRROLE DERIVATIVE; SIMVASTATIN; UBIDECARENONE; VERAPAMIL; WARFARIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DRUG SCREENING; DRUG WITHDRAWAL; ENZYME DEFICIENCY; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY FAILURE; LIVER TOXICITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOSITIS; PATIENT MONITORING; PRACTICE GUIDELINE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

CREATINE KINASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MUSCULAR DISEASES; RISK FACTORS;

EID: 33645107206     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000202691.52352.55     Document Type: Review

References (64)

1. Maron DJ, Fazio S, Linton M. Current perspectives on statins. Circulation 2000;101:207-213.
2. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 2001;24:258-272.
3. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690.
4. Fine D. Statin-Related Muscle Toxicity. Adv Stud Med 2003;3:554-560.
5. Pasternak RC, Smith SC Jr, Bairey-Merz C, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106:1024-1028.
6. Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep 2002;4:34-41.
7. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials. Circulation 2002;105:2341-2346.
8. Federman DG, Hussain F, Walters AB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J 2001;94:1023-1026 .
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
11. Graham D, Staffa J, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. N Engl J Med 2004;292:2585-2590.
12. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Final Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Vol. 2004: National Heart Blood and Lung Institute, 2002.
13. Miller LJ. Postpartum depression. JAMA 2002;287:762-765.
14. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
15. Weismantel D, Danis P. Clinical inquiries: what laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents? J Fam Pract 2001;50:927-928.
16. Sniderman AD. Is there value in liver function test and creatine phospokinase monitoring with statin use? Am J Cardiol 2004; 94(suppl): 30F-34F.
17. Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurement in a primary care setting. Arch Intern Med 2003;163:688-692.
18. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585.
19. Waters D. Statins and safety: applying the results of randomized trials to clinical practice. Am J Cardiol 2003;92:692-695.
20. Wortmann RL. Lipid Lowering Agents and Myopathy. Curr Opin Rheumatol 2002;14:643-647.
21. Nawarskas J. HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev 2005;13:76-79.
22. Chiang C, Pella D, Singh R. Coenyzme Q10 and adverse effects of statins. J Nutritional and Environmental Medicine 2004;14:17-28.
23. Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q 10 level in the blood of patients at risk for cardiovascular disease stroke. Arch Neurol 2004;61:889-892.
24. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of CoQ10: a review of animal and human publications. BioFactors 2003;18:101-111.
25. Murray M. Encyclopedia of Nutritional Supplements. Rocklin, CA: Prima Health, 1996.
26. Coenzyme Q10 monograph. Vol. 2005: Natural Medicines Comprehensive Database, 2005.
27. Simons LA, Sullivan DR. Lipid-modifying drugs. Med J Aust 2005;182: 286-289.
28. Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999;138:151-155.
29. Bolego C, Baetta R, Bellosta S, et al. Safety considerations for statins. Curr Opin Lipidol 2002;13:637-644.
30. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95: 120-122.
31. Dujovne CA. Side effects of statins: hepatitis versus 'transaminitis': myositis versus 'CPKitis'. Am J Cardiol 2002;89:1411-1413.
32. Gotto AM Jr. Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med 2003;163:657-659.
33. de Denus S, Spinler SA, Miller K, Peterson A. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24:584-591.
34. Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-1292.
35. Tice S, Parry D. Medications that require hepatic monitoring. Hosp Pharm 2001;36:456-464.
36. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolmia. Ann Pharmacother 1995;29:743-759.
37. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-1380.
38. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-1271.
39. Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J 2003;79:307-312.
40. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-314.
41. Muldoon MF, Manuck SB, Mendelsohn AB, et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 2001;322:11-15.
42. Yang CC, Jick SS, Jick A. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003; 163: 1926-1932.
43. Bjerre LM, LeLorier J. Do statins cause cancer? a meta-analysis of large randomized clinical trials. Am J Med 2001; 110: 716-23.
44. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005;114:643-647.
45. Muck AO, Seeger H, Wallwiener D. Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 2004;42:695-700.
46. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy P. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-880.
47. Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 2003;23:726-730.
48. Golomb BA, Criqui MH, White HL, Dimsdale J. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials 2004;25:178-202.
49. Pietro Maggioni A. Debate: Should Statins be Used in Patients with Heart Failure. Curr Control Trials Cardiovasc Med 2001;2:266-7.
50. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-1940.
51. Silver MA, Langsjoen PH, Szabo S, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol 2004;94:1306-1310.
52. Packard C. Improving outcomes through statin therapy: a review of ongoing trials. Eur Heart J 2004;(Suppl A):A28-A31.
53. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;15:1567-1573.
54. Strey CH, Young JM, Molyneux SL. et al. Endothlium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 2005;179:201-206.
55. Hargreaves IP. Ubiquinone: cholesterol's reclusive cousin. Ann Clin Biochem 2003;40:207-218.
56. Baggio E, Gandini R, Plancher A, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure: CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994; 15:s287-s294.
57. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig 1993;71:S134-S136.
58. Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure: the Q10 Study Group. J Card Fail 1995;1:101-7.
59. Ishiyama T, Morita Y, Toyama S, et al. A clinical study of the effects of coenzyme Q on congestive heart failure. Jpn Heart J 1976;17:32-42.
60. Morelli V, Zoorob RJ. Alternative therapies, II: congestive heart failure and hypercholesterolemia. Am Fam Physician 2000;62:1325-1330.
61. Rodenburg J, Vissers MN, Wiegman A, et al. Familial hypercholesterolemia in children. Curr Opin Lipidol 2004;15:405-411.
62. Stein EA, Illingworth DR, Kwiterovich P Jr, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999;281:137-144.
63. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002;106: 2231-7.
64. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, controlled trial. JAMA 2004;292:331-337.